RxDoctor Payments Data

Allan Rodriguez, MD

Infectious Disease · Miami, FLNPI 1720010796

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,550 of the $14,656 with a category attached, or 72.0%. Gilead accounts for 91.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $7,620 and has fallen 57.8% since, to $3,213 in 2025.

$14,656in general payments, 2019–2025

Across 103 payments — averaging $142.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$13K
  • Viiv Healthcare Company$583
  • Janssen Products, LP$389
  • Merck$133
  • Theratechnologies Inc.$82
  • Johnson & Johnson$52
  • plus $66 from 2 others
$326,295in research payments, 2019–2025

Across 3 payments — averaging $108,765 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$326K

What the payments were for

  • Consulting fees$10,55072%
  • Speaking & faculty fees$40%
  • Travel & lodging$1,52210%
  • Food & beverage$2,19115%
  • Education$3893%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,656 in reported general payments places this provider in the 85th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$6,550
Medicare patients
36
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala173$692,456
TivicayDolutegravir Sodium128$331,346
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf61$306,970
SerostimSomatropin14$247,798
DescovyEmtricitabine/Tenofov Alafenam83$175,897
DovatoDolutegravir Sodium/Lamivudine56$168,880
TriumeqAbacavir/Dolutegravir/Lamivudi24$84,976
PrezcobixDarunavir/Cobicistat26$62,839
JulucaDolutegravir/Rilpivirine16$51,043
PifeltroDoravirine28$49,386
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$38,452
JanuviaSitagliptin Phosphate40$22,413
JardianceEmpagliflozin28$18,595
PrezistaDarunavir15$16,053
FarxigaDapagliflozin Propanediol22$12,784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$13,350$868,353256 claims
Viiv Healthcare CompanyTivicay, Dovato, Triumeq, Juluca$583$636,244224 claims
Janssen Products, LPSymtuza$389$306,97061 claims
MerckPifeltro, Januvia$133$71,79968 claims
Johnson & JohnsonPrezcobix$52$62,83926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →